STOCK TITAN

Cellectis - CLLS STOCK NEWS

Welcome to our dedicated news page for Cellectis (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cellectis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cellectis's position in the market.

Rhea-AI Summary
Cellectis announces pre-clinical data on MUC1-CAR T-cells to target solid tumors at SITC 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences clinical trial
-
Rhea-AI Summary
Total number of shares in the capital and voting rights as of 08/31/2023 are 55,583,768 and 61,519,936 respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, provided business updates and preliminary financial results for the six-month period ending June 30, 2023. Clinical trials for UCART22, UCART20x22, and UCART123 are ongoing. Preclinical data on HBB gene correction and TALE Base Editors were presented. The company appointed Cécile Chartier as Director. Cash position as of June 30, 2023, was $89 million. Full financial statements for Q2 2023 will be released soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
-
Rhea-AI Summary
Euronext Growth: FR0010425595 Shares and Voting Rights Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
-
Rhea-AI Summary
Cellectis S.A., a clinical-stage biotechnology company, will report financial results for Q2 2023 on August 3, 2023. An investor conference call and webcast will follow on August 4, 2023, providing updates on business activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences earnings
Rhea-AI Summary
Cellectis S.A. has appointed Cécile Chartier, Ph.D., as a Director of the Company's Board of Directors. Dr. Chartier brings extensive experience in the development of cell and gene therapies, making her a valuable asset to the Company. She currently serves as Chief Scientific Officer at NextVivo, Inc. and has previously held positions at Iovance Biotherapeutics, Inc. and OncoMed Pharmaceuticals. Dr. Chartier's expertise will contribute to the advancement of Cellectis' product candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
management
-
Rhea-AI Summary
French company announces its latest shareholder information. As of June 30, 2023, the total number of shares in the capital is 55,583,768 and the total number of voting rights is 61,505,063.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
Cellectis

Nasdaq:CLLS

CLLS Rankings

CLLS Stock Data

203.24M
33.22M
12.13%
18.83%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
France
Paris

About CLLS

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.